Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment.

IF 2.7 4区 医学 Q3 IMMUNOLOGY Immunotherapy Pub Date : 2024-09-13 DOI:10.1080/1750743x.2024.2399498
Sofia Tzoumpa,Béatrice Villette,Florence Granel-Brocard,Caroline Dutriaux,Alexandre Memmi,Geraldine Jeudy,Victor Tafani,Melanie Saint-Jean,Charlee Nardin,Elisa Funck-Brentan,Yannick Le Corre,Gaëlle Quereux,Eve Maubec
{"title":"Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment.","authors":"Sofia Tzoumpa,Béatrice Villette,Florence Granel-Brocard,Caroline Dutriaux,Alexandre Memmi,Geraldine Jeudy,Victor Tafani,Melanie Saint-Jean,Charlee Nardin,Elisa Funck-Brentan,Yannick Le Corre,Gaëlle Quereux,Eve Maubec","doi":"10.1080/1750743x.2024.2399498","DOIUrl":null,"url":null,"abstract":"Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"14 1","pages":"1-9"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743x.2024.2399498","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
治疗转移性黑色素瘤的免疫检查点抑制剂诱发无菌性鼻窦炎。
免疫介导的鼻窦炎很少被描述,很容易被漏诊。我们开展了一项全国性多中心回顾性研究,重点关注接受免疫检查点抑制剂(ICIs)治疗黑色素瘤的患者中出现的免疫介导的鼻窦炎症状。研究共纳入了 12 名患者(50% 为女性,中位年龄为 58 岁)。总体而言,临床旁评估、抗生素/抗组胺药治疗无效、使用免疫抑制剂和/或停用 ICI 后症状有所改善,以及同时存在多种免疫相关不良事件,均表明其病因为非感染性。认识到这种毒性对于限制诊断徘徊和适当治疗至关重要。然而,还需要进行更多的流行病学研究,以评估其作为一种潜在的免疫相关不良事件的发生率及其在接受 ICIs 治疗的患者中的预后价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Immunotherapy
Immunotherapy 医学-免疫学
CiteScore
5.00
自引率
3.60%
发文量
113
审稿时长
6-12 weeks
期刊介绍: Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
期刊最新文献
Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature. Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China. ctDNA-guided adjuvant immunotherapy in colorectal cancer. Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance? Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1